top of page
OCTOBER 18, 2021 - Nature's Biopharma Dealmakers
Antimicrobials standing guard: Amicrobe engineers biologics-as-materials that are applied locally in surgery and trauma to prevent and treat life-threatening infections.
AUGUST 27, 2019 - SAN DIEGO, CA
Dr. Bevilacqua gives invited presentation "Amicidin-alpha and Amicidin-beta: Amino acid block copolymers in development for prevention and treatment of infection in surgery and trauma" at the Fall 2019 American Chemical Society conference
AUGUST 20, 2018 - SILVER SPRING, MD
Dr. Bevilacqua an invited panelist for FDA workshop “Development of Non-Traditional Therapies for Bacterial Infections”
JUNE 14, 2018 - WASHINGTON, DC
Dr. Michael Bevilacqua, Amicrobe’s founder and CEO, was an invited speaker and panelist at an FDA supported meeting on the topic of developing “… Emerging Non-traditional Antibiotics”.
OCTOBER 24, 2017 - CARLSBAD, CA
Amicrobe, Inc. announces receipt of $2.48M award from award from CARB-X to accelerate development of Amicidin-β for treatment of life-threatening infections in surgery and trauma
bottom of page